{
    "title": "Biogen CEO bets on Alzheimer's drug, pipeline to return to growth",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11753907/Biogen-sees-modest-2023-revenue-Alzheimers-disease-drug.html",
    "date": "2023-02-15",
    "keywords": [
        "company",
        "leqembi",
        "revenue",
        "approval",
        "biogen",
        "year",
        "share",
        "treatment",
        "depression",
        "drug",
        "zuranolone",
        "growth",
        "spinraza",
        "launch",
        "ceo",
        "profit",
        "fourthquarter",
        "executive",
        "officer",
        "christopher",
        "viehbacher",
        "wednesday",
        "industry",
        "november",
        "time",
        "competition",
        "tecfidera",
        "sclerosis",
        "atrophy",
        "aduhelm",
        "co",
        "ltd",
        "investor",
        "sentiment",
        "couple",
        "way",
        "situation",
        "briefing",
        "order",
        "day",
        "morning",
        "trading",
        "midsingle",
        "digit",
        "quarter",
        "summer",
        "insurance",
        "coverage",
        "medicare",
        "amp",
        "medicaid",
        "psychiatry",
        "immunology",
        "lot",
        "point",
        "sanofi",
        "deal",
        "genzyme",
        "openness",
        "look",
        "forecast",
        "slump",
        "wall",
        "street",
        "refinitiv",
        "roy",
        "bengaluru",
        "editing",
        "anil",
        "dsilva",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}